EUCTR2004-001918-13-GB进行中（未招募）不适用
Randomised induction and post induction therapy in older patients (>=61 years of age) with acute myeloid leukaemia (AML) and refractory anaemia with excess blasts (RAEB, RAEB-t) - HOVON 43
niversity of Wales College of Medicine0 个研究点目标入组 800 人开始时间: 2005年7月25日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 800
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- age 61 years or over
- •- WHO performance score < 3
- •- informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- impaired renal or hepatic function
- •-previous chemotherapy
研究者
相似试验
已完成
不适用
Randomised induction and post-induction therapy in adult patients (less than or equal to 60 years of age) with acute myelocytic leukaemia (AML) or refractory anaemia with excess of blasts (RAEB, RAEB-t) with IPSS score greater than or equal to 1.5Acute myeloid leukaemia (AML)Myeloid leukaemiaCancerISRCTN38648181Dutch Haemato-Oncology Association (Stichting Hemato-Oncologie Volwassenen Nederland) (HOVON) (Netherlands)800
已完成
不适用
Randomized induction and post induction therapy in older patients (>= 61 yrs of age) with acute myelocytic leukemia (AML) and refractory anemia with excess of blasts (RAEB, RAEB-t).Acute myelocytic leukemia, RAEB, RAEB-t.NL-OMON21122Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON)P/a HOVON Data CenterErasmus MC - DanielPostbus 5201NL-3008 AE RotterdamTel: 010 4391568Fax: 010 4391028e-mail: hdc@erasmusmc.nl800
已完成
3 期
Randomised induction and post induction therapy in older patients (greater than or equal to 61 years of age) with Acute Myelocytic Leukaemia (AML) and Refractory Anaemia with Excess of Blasts (RAEB, RAEB-t)CancerISRCTN77039377Dutch Haemato-Oncology Association (Stichting Hemato-Oncologie Volwassenen Nederland) (HOVON) (Netherlands)800
尚未招募
3 期
Effects of standard induction therapy vs. no induction in renal transplant recipients at low immunological risk of graft rejectioCTRI/2024/01/061771Post Graduate Institute of Medical Education and Research, Chandigarh.
已完成
3 期
Phase III Randomized Study of Induction Therapy Comparing Daunorubicin With Idarubicin Followed By Consolidation Therapy Comparing High-Dose Cytarabine With Sequential Multiagent Chemotherapy in Patients With Previously Untreated De Novo Acute Myeloid Leukemia (JALSG AML201 Study)Acute Myeloid LeukemiaJPRN-C000000157Japan Adult Leukemia Study Group850